Seroprevalence of anti-microbial antibodies in the normal healthy population with implications in chronic diseases
P. Zhang, L. M. Minardi, J. T. Kuenstner, S. M. Zekan, R. Kruzelock
Abstract
We have previously discovered a panel of anti-microbial antibodies from patients with Crohns disease (CD) and Sjogrens syndrome (Sjo). We have also demonstrated the increase of these anti-microbial antibodies in other autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis in a small number of cases. The seroprevalence of these antibodies in the normal healthy population is unknown. We set to survey the normal population for these anti-microbial antibodies. We collected 288 blood samples from the donor units of the leukocyte-reduced red blood cells from the American Red Cross, and examined the presence of the anti-microbial antibodies in these blood samples using direct ELISA assays established in our laboratory using the recombinant microbial protein antigens. Our results showed that the prevalence of RPOB antibody in the normal blood donor population is 2.4% (7 positive of 288 samples). The prevalence of EF-G antibody is 4.2% (12 positive of 288 samples), ATP5a 5.2% (15 positive), Hsp65 2.8% (8 positive), EF-Tu 5.6% (16 positive), and NMPC 4.2% (12 positive). Meanwhile, in 109 patients with Crohns disease and 28 patients with Sjogrens syndrome, these anti-bacterial antibodies are significantly increased (p<0.001). These results indicate that the specific anti-microbial antibodies within the normal general population are uncommon, but frequent in chronic disease states. The presence of increased anti-microbial antibodies in the blood of patients but not in normal controls can serve as biomarkers for chronic diseases such as Crohns disease and Sjogrens, and their presence indicates abnormal B-cell/plasma cell function in response to the commensal/pathogenic microbes. Since the antigens were derived from the common microbes present on the surface of the normal population, the antimicrobial antibodies in patients with diseases but not in the normal population suggest a deficient clearance of the microbes from the circulation by the innate immunity system in chronic diseases. These results also raise questions of bacterial vaccination using whole bacterial extracts as these anti-bacterial antibodies appear pathogenic rather than protective, offering fresh thinking in designing bacterial vaccines as preventive or therapeutic measures in chronic diseases such as Crohns disease and Sjogrens Disease.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Cross reactivity of antibodies against microbial proteins to human tissues as basis of Crohns disease and other autoimmune diseases
Peilin Zhang, Lawrence M. Minardi, … Rusty Kruzelock·bioRxiv·Apr 23, 2017
- Autoantibodies and anti-microbial antibodies: Homology of the protein sequences of human autoantigens and the microbes with implication of microbial etiology in autoimmune diseases
Peilin Zhang·bioRxiv·Aug 29, 2018
- Apoptotic bodies from patients with Sjogren's disease drive atypical memory B cell and macrophage activation and autoantibody production
Adrian Y. S. Lee, Bo Shi, … Joanne H. Reed·bioRxiv·Jul 20, 2026
- Serum and Tear Autoantibodies from NOD and NOR Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren's Disease
Shruti Singh Kakan, Sara Abdelhamid, … Sarah F. Hamm‐Alvarez·Frontiers in ImmunologyPeer-reviewed·Jan 28, 2025
- Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease
C. Eriksen, N. B. Danneskiold-Samsoe, … S. Brix·bioRxiv·Jun 30, 2023
- Human monoclonal antibodies reveal subdominant gonococcal and meningococcal cross-protective antigens
Marco Troisi, Monica Fabbrini, … Rino Rappuoli·Science Translational MedicinePeer-reviewed·May 21, 2025